Vivtex vs Illumina

Side-by-side comparison of AI visibility scores, market position, and capabilities

Illumina leads in AI visibility (74 vs 52)
Vivtex logo

Vivtex

ChallengerBioTech

Oral Biologics Drug Delivery

Signed $2.1B Novo Nordisk collaboration (Feb 2026). Platform enables oral delivery of proteins and peptides (historically injection-only). MIT Langer lab spinout.

AI VisibilityBeta
Overall Score
C52
Category Rank
#67 of 198
AI Consensus
84%
Trend
stable
Per Platform
ChatGPT
52
Perplexity
51
Gemini
50

About

Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historically required injection because they are degraded by stomach acid and too large to absorb through the intestinal wall. In February 2026, Vivtex signed a $2.1 billion collaboration agreement with Novo Nordisk for the development of oral formulations of biologic drugs in obesity, diabetes, and metabolic disease.

Full profile
Illumina logo

Illumina

LeaderLife Sciences & BioTech

Genomics & Sequencing

World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.

AI VisibilityBeta
Overall Score
B74
Category Rank
#5 of 198
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
74
Perplexity
79
Gemini
76

About

Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.

Full profile

AI Visibility Head-to-Head

52
Overall Score
74
#67
Category Rank
#5
84
AI Consensus
76
stable
Trend
stable
52
ChatGPT
74
51
Perplexity
79
50
Gemini
76
54
Claude
69
47
Grok
78

Key Details

Category
Oral Biologics Drug Delivery
Genomics & Sequencing
Tier
Challenger
Leader
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Vivtex
Oral Biologics Drug Delivery
Only Illumina
Genomics & Sequencing

Integrations

Only Vivtex
Only Illumina

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.